ACTU Earnings — Actuate Therapeutics, Inc. Common stock Post-ER Performance | BigEarnings
ACTU — Actuate Therapeutics, Inc. Common stock
XNAS · Healthcare · Biotechnology
Price$2.02
Market Cap$48.3M
P/E—
52W Range$1.58 – $11.70
Next Earnings2026-08-13
About Actuate Therapeutics, Inc. Common stock
Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.
